Asymmetric Synthesis of L-869,298, a Potent PDE4 Inhibitor

P. D. O’Shea; C. Chen; W. Chen; P. Dageneau; L. F. Frey; E. J. J. Grabowski; K. M. Marcantonio; R. A. Reamer; L. Tan; R. D. Tillyer; A. Roy; X. Wang; D. Zhao

doi:10.1055/s-2005-865353

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000131.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Synfacts 2005(0): 0015-0015
DOI: 10.1055/s-2005-865353

Synthesis of Natural Products and Drugs

Asymmetric Synthesis of L-869,298, a Potent PDE4 Inhibitor

Contributor(s): Philip Kocienski
P. D. O’Shea*, C. Chen*, W. Chen, P. Dageneau, L. F. Frey, E. J. J. Grabowski, K. M. Marcantonio, R. A. Reamer, L. Tan, R. D. Tillyer, A. Roy, X. Wang, D. Zhao
Merck Frosst Centre for Therapeutic Research, Quebec, Canada; Merck Research Laboratories, Rahway, USA

Further Information

Publication History

Publication Date:
20 July 2005 (online)

Permissions and Reprints

Significance

The target molecule inhibits phosphodiesterase-4 (PDE4), an enzyme that hydrolyzes cAMP. It is a potential drug for the treatment of asthma and chronic obstructive pulmonary disease.